Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT07209215 · ClinicalTrials.gov registry record · Phase 2
ctDNA-Informed Management of Early-Stage Rectal Cancer
A Phase 2 study, sponsored by University of California, Davis.
- Not yet
- Registry status
- Phase 2
- Development phase
- 200
- Enrollment target
NCT07209215 is a Phase 2 study that has not yet begun recruiting, run by University of California, Davis. The registered enrollment target is 200 participants.
The verdict
NCT07209215, a Phase 2 study, has not yet begun recruiting, sponsored by University of California, Davis.
- NOT YET RECRUITING
- Registry status
- Phase 2
- Development phase
- 200 participants
- Enrollment target
Study Summary
This is a phase 2 pragmatic study to examine the utility of ctDNA-informed treatment management for participants with early-stage rectal cancer using the Signatera Genome assay. The primary aims are to 1) assess pathologic complete response (path CR) in the ctDNA informed management arm; 2) assess pathologic complete response (path CR) in the post total neoadjuvant therapy (TNT) standard of care (SOC) surgery arm; and 3) assess disease free survival (DFS) in the ctDNA informed management arm.
Interventions
- DRUG Signatera Genome ultra-sensitive ctDNA blood test + total neoadjuvant therapy (TNT)
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 200 participants |
| Start Date | 2026-03 |
| Est. Completion | 2028-05 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT07209215
The ClinicalTrials.gov registry entry for NCT07209215 describes a study currently listed as not yet recruiting, categorized as Phase 2. The registered enrollment target is 200 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is University of California, Davis, which has 657 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which Signatera Genome ultra-sensitive ctDNA blood test + total neoadjuvant therapy (TNT) is the first listed.
NCT07209215 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT07209215 about?
NCT07209215 is a clinical study titled "ctDNA-Informed Management of Early-Stage Rectal Cancer". This is a phase 2 pragmatic study to examine the utility of ctDNA-informed treatment management for participants with early-stage rectal cancer using the Signatera Genome assay. The primary aims are to 1) assess pathologic complete response (path CR) in the ctDNA informed management arm; 2) assess p...
What is the current status of trial NCT07209215?
This trial is currently not yet recruiting. It is a Phase 2 study. The enrollment target is 200 participants. The study started on 2026-03. Estimated completion is 2028-05.
What interventions are being tested in trial NCT07209215?
The interventions under investigation include: Signatera Genome ultra-sensitive ctDNA blood test + total neoadjuvant therapy (TNT) (DRUG).
Who is sponsoring clinical trial NCT07209215?
This trial is sponsored by University of California, Davis, which has 657 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.